Subtype
Head and Neck Carcinoma
CI-CAN-00000950Explore in graph →
1,013 active trials15 approved drugs119 evidence items
Loading cancer entity…
Subtype
CI-CAN-00000950Explore in graph →
Clinical trials
2,921 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (347)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04489888 | A Study of Pembrolizumab (MK-3475) Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (MK-3475-B10/KEYNOTE B10) | completed | Phase 4 | 101 | Merck Sharp & Dohme LLCINDUSTRY | 5 | Jun 19, 2025 | clinicaltrials |
| NCT01344356 | Stereotactic Body Radiotherapy for Head and Neck Tumors | completed | Phase 4 | 19 | Mercy ResearchOTHER | 1 | Apr 10, 2020 | clinicaltrials |
| NCT03998696 | An Experimental Study to Compare Treatment Response and Toxicities of Concurrent Chemoradiation With Weekly Cisplatin and Three Weekly Cisplatin in Locally Advanced Head and Neck Cancer.(HNC) | completed | Phase 4 | 60 | Bangabandhu Sheikh Mujib Medical University, Dhaka, BangladeshOTHER | 1 | Jun 28, 2019 | clinicaltrials |
Data updated 22 days agoSource updated Jun 19, 2025source: clinicaltrials